Rethinking global launch sequencing: Reinventing pharma’s playbook for a new era

Global launch sequencing is entering a new era. Traditional “one-size-fits-all” approaches, often anchored in US-first strategies and milestone-driven timelines, are being challenged by increasing policy complexity, evolving evidence and HTA requirements, and rising commercial pressures.

Emerging dynamics such as Most Favored Nation (MFN)-style pricing and tighter HTA frameworks are intensifying interdependencies across markets and fundamentally reshaping how companies prioritize, and sequence launches globally.

In this roundtable discussion, our experts are joined by two senior industry leaders to explore how launch sequencing decisions are evolving in real-world settings, and how companies are responding to these shifts in practice.

Drawing on recent interviews with senior pharma and biotech leaders across the US and Europe, the discussion brings together different perspectives on how organizations are navigating trade-offs between speed, price sustainability,…